S100 calcium binding protein B as a biomarker of delirium duration in the intensive care unit - An exploratory analysis

Babar Khan, Marker O. Farber, Noll Campbell, Anthony Perkins, Nagendra K. Prasad, Siu Hui, Douglas K. Miller, Enrique Calvo-Ayala, John D. Buckley, Ruxandra Ionescu, Anantha Shekhar, E. Wesley Ely, Malaz Boustani

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Currently, there are no valid and reliable biomarkers to identify delirious patients predisposed to longer delirium duration. We investigated the hypothesis that elevated S100 calcium binding protein B (S100β) levels will be associated with longer delirium duration in critically ill patients. Methods: A prospective observational cohort study was performed in the medical, surgical, and progressive intensive care units (ICUs) of a tertiary care, university affiliated, and urban hospital. Sixty-three delirious patients were selected for the analysis, with two samples of S100β collected on days 1 and 8 of enrollment. The main outcome measure was delirium duration. Using the cutoff of <0.1 ng/mL and ≥0.1 ng/mL as normal and abnormal levels of S100β, respectively, on day 1 and day 8, four exposure groups were created: Group A, normal S100β levels on day 1 and day 8; Group B, normal S100β level on day 1 and abnormal S100β level on day 8; Group C, abnormal S100β level on day 1 and normal on day 8; and Group D, abnormal S100β levels on both day 1 and day 8. Results: Patients with abnormal levels of S100β showed a trend towards higher delirium duration (P=0.076); Group B (standard deviation) (7.0 [3.2] days), Group C (5.5 [6.3] days), and Group D (5.3 [6.0] days), compared to patients in Group A (3.5 [5.4] days). Conclusion: This preliminary investigation identified a potentially novel role for S100β as a biomarker for delirium duration in critically ill patients. This finding may have important implications for refining future delirium management strategies in ICU patients.

Original languageEnglish
Pages (from-to)855-861
Number of pages7
JournalInternational Journal of General Medicine
Volume6
DOIs
StatePublished - 2013

Fingerprint

Calcium-Binding Proteins
Delirium
Intensive Care Units
Biomarkers
Critical Illness
Urban Hospitals
Tertiary Healthcare
Critical Care
IgA receptor
Observational Studies
Cohort Studies
Outcome Assessment (Health Care)

Keywords

  • Astrocytes
  • Blood-brain barrier
  • Coma
  • S100β

ASJC Scopus subject areas

  • Medicine(all)

Cite this

S100 calcium binding protein B as a biomarker of delirium duration in the intensive care unit - An exploratory analysis. / Khan, Babar; Farber, Marker O.; Campbell, Noll; Perkins, Anthony; Prasad, Nagendra K.; Hui, Siu; Miller, Douglas K.; Calvo-Ayala, Enrique; Buckley, John D.; Ionescu, Ruxandra; Shekhar, Anantha; Ely, E. Wesley; Boustani, Malaz.

In: International Journal of General Medicine, Vol. 6, 2013, p. 855-861.

Research output: Contribution to journalArticle

Khan, Babar ; Farber, Marker O. ; Campbell, Noll ; Perkins, Anthony ; Prasad, Nagendra K. ; Hui, Siu ; Miller, Douglas K. ; Calvo-Ayala, Enrique ; Buckley, John D. ; Ionescu, Ruxandra ; Shekhar, Anantha ; Ely, E. Wesley ; Boustani, Malaz. / S100 calcium binding protein B as a biomarker of delirium duration in the intensive care unit - An exploratory analysis. In: International Journal of General Medicine. 2013 ; Vol. 6. pp. 855-861.
@article{2489da1c26804bc78b3a3a6d6dd56fd1,
title = "S100 calcium binding protein B as a biomarker of delirium duration in the intensive care unit - An exploratory analysis",
abstract = "Background: Currently, there are no valid and reliable biomarkers to identify delirious patients predisposed to longer delirium duration. We investigated the hypothesis that elevated S100 calcium binding protein B (S100β) levels will be associated with longer delirium duration in critically ill patients. Methods: A prospective observational cohort study was performed in the medical, surgical, and progressive intensive care units (ICUs) of a tertiary care, university affiliated, and urban hospital. Sixty-three delirious patients were selected for the analysis, with two samples of S100β collected on days 1 and 8 of enrollment. The main outcome measure was delirium duration. Using the cutoff of <0.1 ng/mL and ≥0.1 ng/mL as normal and abnormal levels of S100β, respectively, on day 1 and day 8, four exposure groups were created: Group A, normal S100β levels on day 1 and day 8; Group B, normal S100β level on day 1 and abnormal S100β level on day 8; Group C, abnormal S100β level on day 1 and normal on day 8; and Group D, abnormal S100β levels on both day 1 and day 8. Results: Patients with abnormal levels of S100β showed a trend towards higher delirium duration (P=0.076); Group B (standard deviation) (7.0 [3.2] days), Group C (5.5 [6.3] days), and Group D (5.3 [6.0] days), compared to patients in Group A (3.5 [5.4] days). Conclusion: This preliminary investigation identified a potentially novel role for S100β as a biomarker for delirium duration in critically ill patients. This finding may have important implications for refining future delirium management strategies in ICU patients.",
keywords = "Astrocytes, Blood-brain barrier, Coma, S100β",
author = "Babar Khan and Farber, {Marker O.} and Noll Campbell and Anthony Perkins and Prasad, {Nagendra K.} and Siu Hui and Miller, {Douglas K.} and Enrique Calvo-Ayala and Buckley, {John D.} and Ruxandra Ionescu and Anantha Shekhar and Ely, {E. Wesley} and Malaz Boustani",
year = "2013",
doi = "10.2147/IJGM.S51004",
language = "English",
volume = "6",
pages = "855--861",
journal = "International Journal of General Medicine",
issn = "1178-7074",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - S100 calcium binding protein B as a biomarker of delirium duration in the intensive care unit - An exploratory analysis

AU - Khan, Babar

AU - Farber, Marker O.

AU - Campbell, Noll

AU - Perkins, Anthony

AU - Prasad, Nagendra K.

AU - Hui, Siu

AU - Miller, Douglas K.

AU - Calvo-Ayala, Enrique

AU - Buckley, John D.

AU - Ionescu, Ruxandra

AU - Shekhar, Anantha

AU - Ely, E. Wesley

AU - Boustani, Malaz

PY - 2013

Y1 - 2013

N2 - Background: Currently, there are no valid and reliable biomarkers to identify delirious patients predisposed to longer delirium duration. We investigated the hypothesis that elevated S100 calcium binding protein B (S100β) levels will be associated with longer delirium duration in critically ill patients. Methods: A prospective observational cohort study was performed in the medical, surgical, and progressive intensive care units (ICUs) of a tertiary care, university affiliated, and urban hospital. Sixty-three delirious patients were selected for the analysis, with two samples of S100β collected on days 1 and 8 of enrollment. The main outcome measure was delirium duration. Using the cutoff of <0.1 ng/mL and ≥0.1 ng/mL as normal and abnormal levels of S100β, respectively, on day 1 and day 8, four exposure groups were created: Group A, normal S100β levels on day 1 and day 8; Group B, normal S100β level on day 1 and abnormal S100β level on day 8; Group C, abnormal S100β level on day 1 and normal on day 8; and Group D, abnormal S100β levels on both day 1 and day 8. Results: Patients with abnormal levels of S100β showed a trend towards higher delirium duration (P=0.076); Group B (standard deviation) (7.0 [3.2] days), Group C (5.5 [6.3] days), and Group D (5.3 [6.0] days), compared to patients in Group A (3.5 [5.4] days). Conclusion: This preliminary investigation identified a potentially novel role for S100β as a biomarker for delirium duration in critically ill patients. This finding may have important implications for refining future delirium management strategies in ICU patients.

AB - Background: Currently, there are no valid and reliable biomarkers to identify delirious patients predisposed to longer delirium duration. We investigated the hypothesis that elevated S100 calcium binding protein B (S100β) levels will be associated with longer delirium duration in critically ill patients. Methods: A prospective observational cohort study was performed in the medical, surgical, and progressive intensive care units (ICUs) of a tertiary care, university affiliated, and urban hospital. Sixty-three delirious patients were selected for the analysis, with two samples of S100β collected on days 1 and 8 of enrollment. The main outcome measure was delirium duration. Using the cutoff of <0.1 ng/mL and ≥0.1 ng/mL as normal and abnormal levels of S100β, respectively, on day 1 and day 8, four exposure groups were created: Group A, normal S100β levels on day 1 and day 8; Group B, normal S100β level on day 1 and abnormal S100β level on day 8; Group C, abnormal S100β level on day 1 and normal on day 8; and Group D, abnormal S100β levels on both day 1 and day 8. Results: Patients with abnormal levels of S100β showed a trend towards higher delirium duration (P=0.076); Group B (standard deviation) (7.0 [3.2] days), Group C (5.5 [6.3] days), and Group D (5.3 [6.0] days), compared to patients in Group A (3.5 [5.4] days). Conclusion: This preliminary investigation identified a potentially novel role for S100β as a biomarker for delirium duration in critically ill patients. This finding may have important implications for refining future delirium management strategies in ICU patients.

KW - Astrocytes

KW - Blood-brain barrier

KW - Coma

KW - S100β

UR - http://www.scopus.com/inward/record.url?scp=84889020999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889020999&partnerID=8YFLogxK

U2 - 10.2147/IJGM.S51004

DO - 10.2147/IJGM.S51004

M3 - Article

AN - SCOPUS:84889020999

VL - 6

SP - 855

EP - 861

JO - International Journal of General Medicine

JF - International Journal of General Medicine

SN - 1178-7074

ER -